{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T05:38:56Z","timestamp":1663306736459},"reference-count":18,"publisher":"Hogrefe Publishing Group","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Praxis"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:p>Zusammenfassung. Das nephrotische Syndrom wird durch einen renalen Proteinverlust definiert \u2013 damit einhergehend finden sich eine Hypalbumin\u00e4mie im Serum und \u00d6deme. Nicht zu den Diagnosekriterien geh\u00f6rend, aber als h\u00e4ufige Begleiterscheinungen werden eine Hyperlipoprotein\u00e4mie und eine Thrombophilie beobachtet. Zudem besteht eine erh\u00f6hte Infektneigung. Differenziert werden die prim\u00e4ren Ursachen eines nephrotischen Syndroms von sekund\u00e4ren Glomerulopathien als Folge einer systemischen Grunderkrankung. Zur Diagnosesicherung und Absch\u00e4tzung der Prognose wird in den meisten F\u00e4llen eine Nierenbiopsie durchgef\u00fchrt. Prim\u00e4re Formen werden in der Regel mit Steroiden und\/oder anderen Immunsuppressiva behandelt. Bei sekund\u00e4ren Formen steht die Behandlung der Grunderkrankung im Vordergrund. Meist wird eine RAAS-Blockade mittels ACE-Hemmer oder AT-II-Rezeptorblocker etabliert. Zur Kontrolle der \u00d6deme werden Schleifendiuretika eingesetzt. Zus\u00e4tzlich muss die Notwendigkeit der Antikoagulation und einer Statintherapie evaluiert werden.<\/jats:p>","DOI":"10.1024\/1661-8157\/a003223","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T07:30:53Z","timestamp":1554276653000},"page":"347-355","source":"Crossref","is-referenced-by-count":0,"title":["CME: Das nephrotische Syndrom beim Erwachsenen: Pr\u00e4sentation, Abkl\u00e4rung, Therapie"],"prefix":"10.1024","volume":"108","author":[{"given":"Simone C.","family":"Rieder","sequence":"first","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin, Stadtspital Triemli Z\u00fcrich"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars C.","family":"Huber","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin, Stadtspital Triemli Z\u00fcrich"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Trachsler","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Nephrologie, Stadtspital Waid, Z\u00fcrich"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Herberger","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin, Stadtspital Triemli Z\u00fcrich"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"101","reference":[{"key":"c1","unstructured":"KDIGO: Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012; 2: 259\u2013274."},{"key":"c2","doi-asserted-by":"crossref","unstructured":"Llach F: Thromboembolic complications in the nephrotic syndrome. Coagulation abnormalities, renal vein thrombosis and other conditions. Postgrad Med 1984; 76: 111\u2013114, 116\u2013118, 121\u2013123.","DOI":"10.1080\/00325481.1984.11698782"},{"key":"c3","doi-asserted-by":"crossref","unstructured":"Madaio MP, Harrington JT: The diagnosis of glomerular disease, acute glomerulonephritis an the nephrotic syndrome. Arch Intern Med 2001; 161: 25\u201334.","DOI":"10.1001\/archinte.161.1.25"},{"key":"c4","doi-asserted-by":"crossref","unstructured":"Kuhlmann U, B\u00f6hler J, Walb D, Luft FC: Nephrologie: Pathophysiologie \u2013 Klinik \u2013 Nierenersatzverfahren. 6. Aufl. Stuttgart; Thieme: 2008.","DOI":"10.1055\/b-0034-16534"},{"key":"c5","doi-asserted-by":"crossref","unstructured":"Siddall EC, Radhakrishnan J: The pathophysiology of edema formation in the nephrotic syndrome. Kidney Int 2012; 82: 635\u2013642.","DOI":"10.1038\/ki.2012.180"},{"key":"c6","doi-asserted-by":"crossref","unstructured":"Loscalzo J: Venous Thrombosis in the Nephrotic Syndrome. N Engl J Med 2013; 368: 956\u2013958.","DOI":"10.1056\/NEJMcibr1209459"},{"key":"c7","doi-asserted-by":"crossref","unstructured":"Hull RP, Goldsmith DJ: Nephrotic syndrome in adults. BMJ 2008; 336: 1185\u20131189.","DOI":"10.1136\/bmj.39576.709711.80"},{"key":"c8","doi-asserted-by":"crossref","unstructured":"Ogi M, Yokoyama H, Tomosugi N, et al.: Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome. Am J Kidney Dis 1994; 24: 427\u2013436.","DOI":"10.1016\/S0272-6386(12)80899-7"},{"key":"c9","doi-asserted-by":"crossref","unstructured":"Kodner C: Diagnosis and management of nephrotic syndrome in adults. Am Fam Physician 2016; 93: 479\u2013485.","DOI":"10.1007\/978-3-662-52972-0_17"},{"key":"c10","doi-asserted-by":"crossref","unstructured":"Vivarelli M, Massella L, Ruggiero B, Emma F: Minimal change disease. Clin J Am Soc Nephrol 12; 2: 332\u2013345.","DOI":"10.2215\/CJN.05000516"},{"key":"c11","doi-asserted-by":"crossref","unstructured":"Couser WG: Primary membranous nephropathy. Clin J Am Soc Nephrol 2017; 12: 983\u2013997.","DOI":"10.2215\/CJN.11761116"},{"key":"c12","doi-asserted-by":"crossref","unstructured":"Rosenberg AZ, Kopp JB: Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2017; 12: 502\u2013517.","DOI":"10.2215\/CJN.05960616"},{"key":"c13","unstructured":"Gansevoort RT, Sluiter WJ, de Zeeuw D, de Jong PE: Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10: 1963\u20131974."},{"key":"c14","doi-asserted-by":"crossref","unstructured":"Abdallah JG, Schrier RW, Edelstein C, Jennings SD, Wyse B, Ellison DH: Loop diuretic infusion increase thiazide-sensitive Na(+)\/Cl(-)-cotransporter abundance: role of aldosterone. J Am Soc Nephrol 2001; 12: 1335\u20131341.","DOI":"10.1681\/ASN.V1271335"},{"key":"c15","doi-asserted-by":"crossref","unstructured":"Kong X, Yuan H, Fan J, Li Z, Wu T, Jiang L: Lipid-lowering agents for nephrotic syndrome. Cochrane Database Syst Rev 2013; CD005425.","DOI":"10.1002\/14651858.CD005425.pub2"},{"key":"c16","doi-asserted-by":"crossref","unstructured":"Pincus KJ, Hynicka LM: Prophylaxis of thromboembolic events in patients with nephrotic syndrome. Ann Pharmacother 2013; 47: 725\u2013734.","DOI":"10.1345\/aph.1R530"},{"key":"c17","doi-asserted-by":"crossref","unstructured":"Green H, Paul M, Vidal L, Leibovici L: Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients (Review). Cochrane Database Syst Rev 2007; 82: 1052\u20131059. CD005590.","DOI":"10.4065\/82.9.1052"},{"key":"c18","doi-asserted-by":"crossref","unstructured":"Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR: JAMA: Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA 2003; 290: 3101\u20133114.","DOI":"10.1001\/jama.290.23.3101"}],"container-title":["Praxis"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/econtent.hogrefe.com\/doi\/pdf\/10.1024\/1661-8157\/a003223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T04:05:43Z","timestamp":1663214743000},"score":1,"resource":{"primary":{"URL":"https:\/\/econtent.hogrefe.com\/doi\/10.1024\/1661-8157\/a003223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1024\/1661-8157\/a003223"],"URL":"https:\/\/doi.org\/10.1024\/1661-8157\/a003223","relation":{},"ISSN":["1661-8157","1661-8165"],"issn-type":[{"value":"1661-8157","type":"print"},{"value":"1661-8165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}